AFLURIA QUAD, AFLURIA QUAD JUNIOR (Seqirus Pty Ltd)
Product name
AFLURIA QUAD, AFLURIA QUAD JUNIOR
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
197 working days (255)
Active ingredients
influenza virus haemagglutinin
Registration type
EOI
Indication
For the prevention of influenza caused by Influenza Virus, Types A and B contained in the vaccine. Afluria Quad vaccine (suspension for injection) is indicated for use in persons aged 3 years and older. Afluria Quad Junior vaccine (suspension for injection) is indicated for use in children aged 6 months to 35 months inclusive. For full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.